Damon Salvatore's Album: Wall Photos
Antibody contract
manufacturing market is projected to reach USD 17 billion by 2030, claims
Roots Analysis
With over
100 therapeutic monoclonal antibodies and antibody-based products in the
market, the demand for developing and manufacturing of such products is
anticipated to increase beyond the capabilities of innovator companies alone
Roots Analysis has announced the addition of the “Antibody Contract
Manufacturing Market, 2020-2030” report to its list
of offerings.
Although
biopharmaceuticals offer significant profit margins and have been proven to be
effective in treating a myriad of diseases, they are generally associated with
high costs of development and complex manufacturing protocols; this is true for
antibody-based products as well. Presently, there are a number of companies
that claim to offer end-to-end solutions, ranging from antibody development to
commercial production. Further, prevalent trends suggest that sponsor companies
are likely to continue relying on contract service providers for various
aspects of antibody-based product development and manufacturing.
To order this 285+ page report, which features 100+ figures
and 110+ tables, please visit this
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Key Market Insights
Over
100 CMOs presently claim to offer manufacturing services for antibodies
The antibody contract
manufacturing market is currently dominated by the presence of small and
mid-sized companies, which represent 70% of the industry stakeholders. It is
also worth highlighting that more than 55% of CMOs claim to have the
capabilities to manufacture antibodies across all scales of operation
(preclinical, clinical and commercial).
More than 90% service providers are focused on the
production of monoclonal antibodies
However, players
based in Asia are now increasingly focusing on the development of bispecific
antibodies for therapeutic use. It worth highlighting that close to 20% of the
CMOs engaged in this domain claim to offer manufacturing services for both
bispecific antibodies and antibody fragments.
Europe has emerged as a key manufacturing hub for
antibody-based products
More than 120
manufacturing facilities have been established by various players, worldwide;
of these, 40% are in Europe. Additionally, 40% of the total installed capacity
is in Europe, followed by Asia. Some of the prominent regions in Asia include (in
decreasing order of number of manufacturing facilities) China, South Korea,
India, Japan and Taiwan.
More
than 90 partnership agreements have been inked between 2013 and 2019
Majority of these
agreements were focused on manufacturing of various types of antibodies. Other
popular types of collaboration models include process development and
manufacturing agreements (22%), product development and manufacturing
agreements (10%) and licensing agreements (7%).
Multiple
expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such
initiatives were reported to be focused on the expansion of manufacturing facilities,
followed by building new facilities (38%). It is worth noting that close to 50%
of the total number of expansion initiatives were undertaken in Europe, of
which, 25% were in the UK.
Demand
for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during
2020-2025
Given
the fact that there are a number of antibody-based products in the market, the commercial
demand for antibodies is significantly higher than the clinical demand. Across
the three major global regions, North America represent over half of the
overall global manufacturing demand for antibodies.
North
America and Europe are anticipated to capture over 70% of the market share by
2030
However, the market
in the Asia is anticipated to grow at a relatively faster rate. Further,
presently, more than 90% of the antibodies are being developed using mammalian
expression systems, and this trend is unlikely to change significantly in short
to mid-term.
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/295/request-sample.html
Key
Questions Answered
§
Who are the leading CMOs engaged in the production of
antibody-based therapeutics?
§ What
kind of partnership models are commonly adopted by stakeholders in this
industry?
§ What
is the annual clinical and commercial demand for antibody-based products?
§ What
is the current installed capacity for manufacturing of antibodies?
§ What
are the various expansion initiatives undertaken by antibody CMOs?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 17 billion (by 2030) financial opportunity
within the antibody contract manufacturing market has been analyzed across the
following segments:
§ Type
of Antibodies
§ Monoclonal
Antibodies
§ Bispecific
Antibodies
§ ADCs
§ Others
§
Company Size
§ Small
§ Mid-sized
§ Large
/ Very Large
§ Scale
of Operation
§ Preclinical
/ Clinical
§ Commercial
§ Type
of expression system used
§ Mammalian
§ Microbial
§ Key
geographical regions
§ North
America
§ Europe
§ Asia
and RoW
The report features
inputs from eminent industry stakeholders, according to whom antibody
therapeutics developers are increasingly outsourcing their manufacturing operations
owing to complex nature of the overall process, as well as the high investments
associated with setting-up in-house expertise. The report includes detailed
transcripts of discussions held with the following experts:
§ Dietmar
Katinger (Chief Executive Officer, Polymun Scientific)
§ David
C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
§ Claire
Otjes (Marketing Manager, Batavia Biosciences)
The research covers
profiles of key players that offer manufacturing services for antibodies,
featuring a company overview, information on their respective service
portfolios, manufacturing facilities and capabilities, and an informed future
outlook.
§ AGC
Biologics
§ Aldevron
§ AMRI
§ Boehringer
Ingelheim BioXcellence
§ Emergent
BioSolutions
§ Eurofins
CDMO
§ FUJIFILM
Diosynth Biotechnologies
§ KBI
Biopharma
§ Lonza
§ Nitto
Avecia Pharma Services
§ Novasep
§ Pierre
Fabre
§ Samsung
BioLogics
§ Synthon
§ Thermo
Fisher Scientific
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Bispecific Antibody
Therapeutics Market (4th Edition), 2019-2030
2.
Antibody Drug
Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
3.
Antibody Drug
Conjugates Market (5th Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
manufacturing market is projected to reach USD 17 billion by 2030, claims
Roots Analysis
With over
100 therapeutic monoclonal antibodies and antibody-based products in the
market, the demand for developing and manufacturing of such products is
anticipated to increase beyond the capabilities of innovator companies alone
Roots Analysis has announced the addition of the “Antibody Contract
Manufacturing Market, 2020-2030” report to its list
of offerings.
Although
biopharmaceuticals offer significant profit margins and have been proven to be
effective in treating a myriad of diseases, they are generally associated with
high costs of development and complex manufacturing protocols; this is true for
antibody-based products as well. Presently, there are a number of companies
that claim to offer end-to-end solutions, ranging from antibody development to
commercial production. Further, prevalent trends suggest that sponsor companies
are likely to continue relying on contract service providers for various
aspects of antibody-based product development and manufacturing.
To order this 285+ page report, which features 100+ figures
and 110+ tables, please visit this
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Key Market Insights
Over
100 CMOs presently claim to offer manufacturing services for antibodies
The antibody contract
manufacturing market is currently dominated by the presence of small and
mid-sized companies, which represent 70% of the industry stakeholders. It is
also worth highlighting that more than 55% of CMOs claim to have the
capabilities to manufacture antibodies across all scales of operation
(preclinical, clinical and commercial).
More than 90% service providers are focused on the
production of monoclonal antibodies
However, players
based in Asia are now increasingly focusing on the development of bispecific
antibodies for therapeutic use. It worth highlighting that close to 20% of the
CMOs engaged in this domain claim to offer manufacturing services for both
bispecific antibodies and antibody fragments.
Europe has emerged as a key manufacturing hub for
antibody-based products
More than 120
manufacturing facilities have been established by various players, worldwide;
of these, 40% are in Europe. Additionally, 40% of the total installed capacity
is in Europe, followed by Asia. Some of the prominent regions in Asia include (in
decreasing order of number of manufacturing facilities) China, South Korea,
India, Japan and Taiwan.
More
than 90 partnership agreements have been inked between 2013 and 2019
Majority of these
agreements were focused on manufacturing of various types of antibodies. Other
popular types of collaboration models include process development and
manufacturing agreements (22%), product development and manufacturing
agreements (10%) and licensing agreements (7%).
Multiple
expansion initiatives were undertaken by CMOs between 2017 and 2019
More than 50% of such
initiatives were reported to be focused on the expansion of manufacturing facilities,
followed by building new facilities (38%). It is worth noting that close to 50%
of the total number of expansion initiatives were undertaken in Europe, of
which, 25% were in the UK.
Demand
for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during
2020-2025
Given
the fact that there are a number of antibody-based products in the market, the commercial
demand for antibodies is significantly higher than the clinical demand. Across
the three major global regions, North America represent over half of the
overall global manufacturing demand for antibodies.
North
America and Europe are anticipated to capture over 70% of the market share by
2030
However, the market
in the Asia is anticipated to grow at a relatively faster rate. Further,
presently, more than 90% of the antibodies are being developed using mammalian
expression systems, and this trend is unlikely to change significantly in short
to mid-term.
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/295/request-sample.html
Key
Questions Answered
§
Who are the leading CMOs engaged in the production of
antibody-based therapeutics?
§ What
kind of partnership models are commonly adopted by stakeholders in this
industry?
§ What
is the annual clinical and commercial demand for antibody-based products?
§ What
is the current installed capacity for manufacturing of antibodies?
§ What
are the various expansion initiatives undertaken by antibody CMOs?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 17 billion (by 2030) financial opportunity
within the antibody contract manufacturing market has been analyzed across the
following segments:
§ Type
of Antibodies
§ Monoclonal
Antibodies
§ Bispecific
Antibodies
§ ADCs
§ Others
§
Company Size
§ Small
§ Mid-sized
§ Large
/ Very Large
§ Scale
of Operation
§ Preclinical
/ Clinical
§ Commercial
§ Type
of expression system used
§ Mammalian
§ Microbial
§ Key
geographical regions
§ North
America
§ Europe
§ Asia
and RoW
The report features
inputs from eminent industry stakeholders, according to whom antibody
therapeutics developers are increasingly outsourcing their manufacturing operations
owing to complex nature of the overall process, as well as the high investments
associated with setting-up in-house expertise. The report includes detailed
transcripts of discussions held with the following experts:
§ Dietmar
Katinger (Chief Executive Officer, Polymun Scientific)
§ David
C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
§ Claire
Otjes (Marketing Manager, Batavia Biosciences)
The research covers
profiles of key players that offer manufacturing services for antibodies,
featuring a company overview, information on their respective service
portfolios, manufacturing facilities and capabilities, and an informed future
outlook.
§ AGC
Biologics
§ Aldevron
§ AMRI
§ Boehringer
Ingelheim BioXcellence
§ Emergent
BioSolutions
§ Eurofins
CDMO
§ FUJIFILM
Diosynth Biotechnologies
§ KBI
Biopharma
§ Lonza
§ Nitto
Avecia Pharma Services
§ Novasep
§ Pierre
Fabre
§ Samsung
BioLogics
§ Synthon
§ Thermo
Fisher Scientific
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Bispecific Antibody
Therapeutics Market (4th Edition), 2019-2030
2.
Antibody Drug
Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
3.
Antibody Drug
Conjugates Market (5th Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis